Knockdown of LINC01929 in breast cancer cell lines reduced cell survival, cell cycle progression, inhibited tumor growth, and altered the expression of genes involved in growth, immune, and antigen presentation pathways. This evidence concerns the gene LINC01929 and breast carcinoma.